000203086 001__ 203086
000203086 005__ 20210129220300.0
000203086 0247_ $$2doi$$a10.1007/s00417-014-2652-0
000203086 0247_ $$2ISSN$$a0065-6100
000203086 0247_ $$2ISSN$$a0376-0200
000203086 0247_ $$2ISSN$$a0721-832X
000203086 0247_ $$2ISSN$$a0721-832x
000203086 0247_ $$2ISSN$$a1435-702X
000203086 0247_ $$2WOS$$aWOS:000347553200004
000203086 0247_ $$2altmetric$$aaltmetric:4104577
000203086 0247_ $$2pmid$$apmid:24827634
000203086 037__ $$aFZJ-2015-05121
000203086 041__ $$aEnglish
000203086 082__ $$a610
000203086 1001_ $$0P:(DE-HGF)0$$aRösch, Sarah$$b0
000203086 245__ $$aThe effects of iodoacetic acid on the mouse retina
000203086 260__ $$aBerlin$$bSpringer$$c2015
000203086 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1438678319_16991
000203086 3367_ $$2DataCite$$aOutput Types/Journal article
000203086 3367_ $$00$$2EndNote$$aJournal Article
000203086 3367_ $$2BibTeX$$aARTICLE
000203086 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000203086 3367_ $$2DRIVER$$aarticle
000203086 520__ $$aBackground:To characterize the effects of intravitreal injections of iodoacetic acid (IAA) in comparison to its systemic application as a measure to induce unilateral photoreceptor degeneration.Methods:Seven-week-old C57BL/6 J mice received either intravitreal injections of IAA or systemic treatment (intraperitoneal vs intravenous) and were observed in the following 5 weeks using ERG, OCT, and histology.Results:Systemic treatment with IAA induced high toxic effects and a high mortality in contrast to the intravitreal injection. Intraperitoneal application had no effect on the retina. Intravenous application of 2 × 30 mg/kg BW IAA (time between injections 3.5 h) resulted in an extinction of the ERG and a thinning of the retina, in particular of the outer nuclear layer (ONL) indicating photoreceptor degeneration. Animals receiving intravitreal injections developed cataracts already at low concentrations (up to 100 % at 0.25 mg/kg BW). Higher intravitreal IAA doses led to extinguished ERGs. In histology, a thinning of the entire retina was observed that was most prominent in the inner part of the retina.Conclusions:In contrast to intraperitoneal administration, intravenous application of IAA led to a selective photoreceptor degeneration. After intravitreal injection, dense cataracts were already observed at concentrations lower than those needed to induce changes in the ERG. ERG results must be interpreted carefully. A thinning of all retinal layers rather than a specific outer retinal degeneration was observed upon intravitreal injection. IAA is not a useful model to induce outer retinal degeneration in mice.
000203086 536__ $$0G:(DE-HGF)POF3-553$$a553 - Physical Basis of Diseases (POF3-553)$$cPOF3-553$$fPOF III$$x0
000203086 588__ $$aDataset connected to CrossRef
000203086 7001_ $$0P:(DE-HGF)0$$aJohnen, Sandra$$b1
000203086 7001_ $$0P:(DE-HGF)0$$aMazinani, Babac$$b2
000203086 7001_ $$0P:(DE-Juel1)131939$$aMüller, Frank$$b3$$ufzj
000203086 7001_ $$0P:(DE-HGF)0$$aPfarrer, Christiane$$b4
000203086 7001_ $$0P:(DE-HGF)0$$aWalter, Peter$$b5$$eCorresponding author
000203086 773__ $$0PERI:(DE-600)1459159-5$$a10.1007/s00417-014-2652-0$$gVol. 253, no. 1, p. 25 - 35$$n1$$p25 - 35$$tGraefe's archive for clinical and experimental ophthalmology$$v253$$x1435-702X$$y2015
000203086 8564_ $$uhttps://juser.fz-juelich.de/record/203086/files/art_10.1007_s00417-014-2652-0.pdf$$yRestricted
000203086 8564_ $$uhttps://juser.fz-juelich.de/record/203086/files/art_10.1007_s00417-014-2652-0.gif?subformat=icon$$xicon$$yRestricted
000203086 8564_ $$uhttps://juser.fz-juelich.de/record/203086/files/art_10.1007_s00417-014-2652-0.jpg?subformat=icon-1440$$xicon-1440$$yRestricted
000203086 8564_ $$uhttps://juser.fz-juelich.de/record/203086/files/art_10.1007_s00417-014-2652-0.jpg?subformat=icon-180$$xicon-180$$yRestricted
000203086 8564_ $$uhttps://juser.fz-juelich.de/record/203086/files/art_10.1007_s00417-014-2652-0.jpg?subformat=icon-640$$xicon-640$$yRestricted
000203086 8564_ $$uhttps://juser.fz-juelich.de/record/203086/files/art_10.1007_s00417-014-2652-0.pdf?subformat=pdfa$$xpdfa$$yRestricted
000203086 909CO $$ooai:juser.fz-juelich.de:203086$$pVDB
000203086 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131939$$aForschungszentrum Jülich GmbH$$b3$$kFZJ
000203086 9131_ $$0G:(DE-HGF)POF3-553$$1G:(DE-HGF)POF3-550$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lBioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences$$vPhysical Basis of Diseases$$x0
000203086 9141_ $$y2015
000203086 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bGRAEF ARCH CLIN EXP : 2013
000203086 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000203086 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000203086 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000203086 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000203086 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000203086 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000203086 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000203086 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000203086 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000203086 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000203086 920__ $$lyes
000203086 9201_ $$0I:(DE-Juel1)ICS-4-20110106$$kICS-4$$lZelluläre Biophysik$$x0
000203086 980__ $$ajournal
000203086 980__ $$aVDB
000203086 980__ $$aI:(DE-Juel1)ICS-4-20110106
000203086 980__ $$aUNRESTRICTED
000203086 981__ $$aI:(DE-Juel1)IBI-1-20200312